The trading price of Pacific Biosciences of California Inc (NASDAQ:PACB) closed higher on Friday, January 17, and closing at $1.64, 2.50% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $1.6 and $1.675. In examining the 52-week price action we see that the stock hit a 52-week high of $7.50 and a 52-week low of $1.16. Over the past month, the stock has lost -20.00% in value.
Pacific Biosciences of California Inc, whose market valuation is $449.14 million at the time of this writing, is expected to release its quarterly earnings report in February. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.18 per share this quarter, however they have predicted annual earnings per share of -0.81 for current year and -0.64 for next year.
Analysts have forecast the company to bring in revenue of 40.68M for the current quarter, with the likely lows of 39.92M and highs of 42M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 155.39M.
On the technical side, indicators suggest PACB has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 50% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned PACB a recommendation rating is 11. Out of them, 4 rate it a Hold, while 6 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Pacific Biosciences of California Inc (PACB) as Underweight, while 1 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that PACB’s price is currently -13.38% off the SMA20 and -16.70% off the SMA50. The RSI metric on the 14-day chart is currently showing 37.71, and weekly volatility stands at 11.02%. When measured over the past 30 days, the indicator reaches 8.90%. Pacific Biosciences of California Inc (NASDAQ:PACB)’s beta value is currently sitting at 1.94, while the Average True Range indicator is currently displaying 0.18. With analysts defining $2-$4 as the low and high price targets, we arrive at a consensus price target of $3 for the trailing 12-month period. The current price is about -21.95% off the estimated low and -143.9% off the forecast high, based on this estimate. Investors will be thrilled if PACB’s share price rises to $3, which is the median consensus price. At that level, PACB’s share price would be -82.93% below current price.
To see how Pacific Biosciences of California Inc stock has been performing in comparison to its peers in the industry, here are the numbers: PACB stock’s performance was 2.50% in the latest trading, and -73.16% in the past year.
An evaluation of the daily trading volume of Pacific Biosciences of California Inc (NASDAQ:PACB) indicates that the 3-month average is 9.91 million. However, this figure has increased over the past 10 days to an average of 11.62.
Currently, records show that 273.81 million of the company’s shares remain outstanding. The insiders hold 11.69% of outstanding shares, whereas institutions hold 83.23%. The stats also highlight that short interest as of 2024-12-31, stood at 56.85 million shares, resulting in a short ratio of 6.69 at that time. From this, we can conclude that short interest is 2200.00 of the company’s total outstanding shares. It is noteworthy that short shares in December were up slightly from the previous month’s figure, which was 54.38 million. However, since the stock’s price has seen -10.38% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
